Literature DB >> 27475809

CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy.

P Di Gennaro1, G Gerlini2, C Urso3, S Sestini2, P Brandani2, N Pimpinelli4, L Borgognoni2.   

Abstract

Electrochemotherapy (ECT) represents an effective local treatment for skin unresectable melanoma metastases with high overall objective response rate. ECT is based on the combination of anti-neoplastic drugs administration and cancer cells electroporation. Whether ECT can also activate the immune system is a matter of debate, however a significant recruitment of dendritic cells in melanoma treated metastases has been described. Herein we investigated immediate and late effects of ECT treatment on T cell subsets in ECT-treated lesions by fluorescent immunohistochemistry. Biopsies from melanoma patients (n = 10) were taken before ECT (t0), at d1 and d14 from treatment. At t0, CD3+CD4+ T cells were the most represented T cells, well detected in the perilesional dermis, particularly at tumour margin, while CD3+CD8+ T cells were less represented. CD4+FOXP3+ T regulatory (Treg) cells were present in the perilesional dermis and within the lesion. ECT induced a significant decrease of CD4+FOXP3+ Treg cells percentage in the perilesional dermis, observed at d1 and at d14 (p < 0.001). CD3+CD8+ T cells frequency significantly increased at d14 from treatment in the perilesional dermis (p < 0.001). Furthermore calreticulin translocation to the plasma membrane, a hallmark of immunogenic cell death, was observed in metastatic cells after ECT. The data reported here confirm that ECT induces a local response, with a lymphoid infiltrate characterized by CD4+FOXP3+ Treg cells decrease and CD3+CD8+ T cells recruitment in the treated lesions. These results might contribute to design novel combinational therapeutic approaches with ECT and immunotherapy in order to generate a systemic long-lasting anti-melanoma immunity.

Entities:  

Keywords:  Electrochemotherapy; ICD; Immunotherapy; Melanoma; TILs; Treg cells

Mesh:

Substances:

Year:  2016        PMID: 27475809     DOI: 10.1007/s10585-016-9814-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  44 in total

1.  Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy.

Authors:  Gianni Gerlini; Serena Sestini; Paola Di Gennaro; Carmelo Urso; Nicola Pimpinelli; Lorenzo Borgognoni
Journal:  Clin Exp Metastasis       Date:  2012-06-27       Impact factor: 5.150

2.  Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation.

Authors:  Lin Min; Siti Aminah Bte Mohammad Isa; Wang Shuai; Cher Boon Piang; Fam Wee Nih; Masayo Kotaka; Christiane Ruedl
Journal:  J Immunol       Date:  2010-03-31       Impact factor: 5.422

Review 3.  Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy.

Authors:  Ruggero Cadossi; Mattia Ronchetti; Matteo Cadossi
Journal:  Future Oncol       Date:  2014-04       Impact factor: 3.404

Review 4.  Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

Authors:  Joannes F M Jacobs; Stefan Nierkens; Carl G Figdor; I Jolanda M de Vries; Gosse J Adema
Journal:  Lancet Oncol       Date:  2012-01       Impact factor: 41.316

Review 5.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

6.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

7.  Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent.

Authors:  Nicola Solari; Francesco Spagnolo; Erica Ponte; Alberto Quaglia; Roberto Lillini; Michela Battista; Paola Queirolo; Ferdinando Cafiero
Journal:  J Surg Oncol       Date:  2013-10-28       Impact factor: 3.454

8.  Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation.

Authors:  Gianni Gerlini; Paola Di Gennaro; Lorenzo Borgognoni
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

Review 9.  Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.

Authors:  Neeharika Srivastava; David McDermott
Journal:  Cancer Manag Res       Date:  2014-06-20       Impact factor: 3.989

10.  Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis.

Authors:  Corrado Caracò; Nicola Mozzillo; Ugo Marone; Ester Simeone; Lucia Benedetto; Gianluca Di Monta; Maria Luisa Di Cecilia; Gerardo Botti; Paolo Antonio Ascierto
Journal:  BMC Cancer       Date:  2013-12-01       Impact factor: 4.430

View more
  6 in total

1.  Calcium electroporation induces tumor eradication, long-lasting immunity and cytokine responses in the CT26 colon cancer mouse model.

Authors:  Hanne Falk; Patrick F Forde; Marie Lund Bay; Uma Maheswari Mangalanathan; Pernille Hojman; Declan M Soden; Julie Gehl
Journal:  Oncoimmunology       Date:  2017-03-17       Impact factor: 8.110

2.  Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma.

Authors:  Noemy Starita; Gianluca Di Monta; Andrea Cerasuolo; Ugo Marone; Anna Maria Anniciello; Gerardo Botti; Luigi Buonaguro; Franco M Buonaguro; Maria Lina Tornesello
Journal:  Infect Agent Cancer       Date:  2017-06-19       Impact factor: 2.965

3.  Establishment and characterization of a new spontaneously immortalized ER-/PR-/HER2+ human breast cancer cell line, DHSF-BR16.

Authors:  Stefania Nobili; Antonella Mannini; Astrid Parenti; Chiara Raggi; Andrea Lapucci; Giovanna Chiorino; Sara Paccosi; Paola Di Gennaro; Vania Vezzosi; Paolo Romagnoli; Tommaso Susini; Marcella Coronnello
Journal:  Sci Rep       Date:  2021-04-16       Impact factor: 4.379

4.  Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.

Authors:  Davide Quaresmini; Alessandra Di Lauro; Livia Fucci; Sabino Strippoli; Ivana De Risi; Angela Monica Sciacovelli; Anna Albano; Gaetano Achille; Massimo Montepara; Sabino Russo; Gabriella Tassone; Michele Guida
Journal:  Front Oncol       Date:  2021-09-16       Impact factor: 6.244

5.  Antitumor Response and Immunomodulatory Effects of Sub-Microsecond Irreversible Electroporation and Its Combination with Calcium Electroporation.

Authors:  Vitalij Novickij; Robertas Čėsna; Emilija Perminaitė; Auksė Zinkevičienė; Dainius Characiejus; Jurij Novickij; Saulius Šatkauskas; Paulius Ruzgys; Irutė Girkontaitė
Journal:  Cancers (Basel)       Date:  2019-11-09       Impact factor: 6.639

6.  Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma.

Authors:  Martina Torchio; Laura Cattaneo; Massimo Milione; Natalie Prinzi; Francesca Corti; Marco Ungari; Andrea Anichini; Roberta Mortarini; Antonio Occhini; Giulia Bertino; Andrea Maurichi; Jorgelina Coppa; Maria Di Bartolomeo; Filippo Guglielmo de Braud; Sara Pusceddu
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.